SILVA DI CESARE

Prof. SILVA DI CESARE

Research Unit of Primary Immunodeficiencies Bambino Gesù Children's Hospital IRCCS, Rome, Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2007 in Cell
Verified
Journal Article
Closed access
BSBenedetto Sacchetti
Benedetto Sacchetti
AFAlessia Funari
Alessia Funari
SMStefano Michienzi
Stefano Michienzi
SCSILVA DI CESARE
SILVA DI CESARE
SPStefania Piersanti
Stefania Piersanti
PBPaolo Bianco
Paolo Bianco

10 October 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MLMichael Lam
Michael Lam
SCSimona Coppola
Simona Coppola
OKOliver H.F. Krumbach
Oliver H.F. Krumbach
GPGiusi Prencipe
Giusi Prencipe
AIAntonella Insalaco
Antonella Insalaco
MTMarco Tartaglia
Marco Tartaglia
Hemophagocytic lymphohistiocytosis (HLH) is characterized by immune dysregulation due to inadequate restraint of overactivated immune cells and is associated with a variable clinical spectrum having overlap with more common pathophysiologies. HLH is difficult to diagnose and can be part of inflammatory syndromes. Here, we identify a novel hematological/autoinflammatory condition (NOCARH syndrome) in four unrelated patients with superimposable features, including neonatal-onset cytopenia with dyshematopoiesis, autoinflammation, rash, and HLH. Patients shared the same de novo CDC42 mutation (Chr1:22417990C>T, p.R186C) and altered hematopoietic compartment, immune dysregulation, and inflammation. CDC42 mutations had been associated with syndromic neurodevelopmental disorders. In vitro and in vivo assays documented unique effects of p.R186C on CDC42 localization and function, correlating with the distinctiveness of the trait. Emapalumab was critical to the survival of one patient, who underwent successful bone marrow transplantation. Early recognition of the disorder and establishment of treatment followed by bone marrow transplant are important to survival.

1 April 2005 in Transplantation
Verified
Journal Article
Closed access
ALAndrea Lamioni
Andrea Lamioni
FPFrancesco Parisi
Francesco Parisi
GIGiancarlo Isacchi
Giancarlo Isacchi
EGEzio Giorda
Ezio Giorda
SCSILVA DI CESARE
SILVA DI CESARE
RCRita Carsetti
Rita Carsetti
Extracorporeal photopheresis (ECP) may represent an alternative to immunosuppression, as a means of reducing rejection after thoracic organ transplantation. The mechanism by which ECP exerts its protective effects has, until now, remained elusive. We analyzed peripheral blood mononuclear cells of four children with chronic heart and lung transplant rejection, who received ECP in addition to conventional immunosuppressive treatment. The effects of ECP were evaluated at each cycle, comparing blood samples from the same patient collected before and after treatment. In vitro, peripheral blood mononuclear cells treated with ECP undergo apoptosis and are phagocytosed by immature dendritic cells, which, in turn, acquire a tolerogenic phenotype. The frequency of T cells, with a regulatory phenotype and strong suppressive activity, was significantly increased in the blood of ECP-treated patients. The immunomodulatory effects of ECP may be explained by its ability to increase the frequency of regulatory T cells with inhibitory action on transplant immune rejection.

1 October 2003 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PAPastore Anna
Pastore Anna
GTGIULIA TOZZI
GIULIA TOZZI
LGLaura Maria Gaeta
Laura Maria Gaeta
EBEnrico Bertini
Enrico Bertini
VSValentina Serafini
Valentina Serafini
FPFiorella Piemonte
Fiorella Piemonte
Increasing evidence suggests that iron-mediated oxidative stress might underlie the development of neurodegeneration in Friedreich's ataxia (FRDA), an autosomal recessive ataxia caused by decreased expression of frataxin, a protein implicated in iron metabolism. In this study, we demonstrate that, in fibroblasts of patients with FRDA, the cellular redox equilibrium is shifted toward more protein-bound glutathione. Furthermore, we found that actin is glutathionylated, probably as a result of the accumulation of reactive oxygen species, generated by iron overload in the disease. Indeed, high-pressure liquid chromatography analysis of control fibroblasts in vivo treated with FeSO4 showed a significant increase in the protein-bound/free GSH ratio, and Western blot analysis indicated a relevant rise in glutathionylation. Actin glutathionylation contributes to impaired microfilament organization in FRDA fibroblasts. Rhodamine phalloidin staining revealed a disarray of actin filaments and a reduced signal of F-actin fluorescence. The same hematoxylin/eosin-stained cells showed abnormalities in size and shape. When we treated FRDA fibroblasts with reduced glutathione, we obtained a complete rescue of cytoskeletal abnormalities and cell viability. Thus, we conclude that oxidative stress may induce actin glutathionylation and impairment of cytoskeletal functions in FRDA fibroblasts.

8 March 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MSMehul Sharma
Mehul Sharma
DLDaniel Leung
Daniel Leung
MMMana Momenilandi
Mana Momenilandi
LJLauren C.W. Jones
Lauren C.W. Jones
LPLucia Pacillo
Lucia Pacillo
STStuart E. Turvey
Stuart E. Turvey
STAT6 (signal transducer and activator of transcription 6) is a transcription factor that plays a central role in the pathophysiology of allergic inflammation. We have identified 16 patients from 10 families spanning three continents with a profound phenotype of early-life onset allergic immune dysregulation, widespread treatment-resistant atopic dermatitis, hypereosinophilia with esosinophilic gastrointestinal disease, asthma, elevated serum IgE, IgE-mediated food allergies, and anaphylaxis. The cases were either sporadic (seven kindreds) or followed an autosomal dominant inheritance pattern (three kindreds). All patients carried monoallelic rare variants in STAT6 and functional studies established their gain-of-function (GOF) phenotype with sustained STAT6 phosphorylation, increased STAT6 target gene expression, and TH2 skewing. Precision treatment with the anti–IL-4Rα antibody, dupilumab, was highly effective improving both clinical manifestations and immunological biomarkers. This study identifies heterozygous GOF variants in STAT6 as a novel autosomal dominant allergic disorder. We anticipate that our discovery of multiple kindreds with germline STAT6 GOF variants will facilitate the recognition of more affected individuals and the full definition of this new primary atopic disorder.

4 July 2006 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
AFAndrea Finocchi
Andrea Finocchi
SCSILVA DI CESARE
SILVA DI CESARE
MRM. L Romiti
M. L Romiti
CCC. Capponi
C. Capponi
Pier Paolo RossiPier Paolo Rossi
Pier Paolo Rossi
CCCaterina Cancrini
Caterina Cancrini